Figure 6
From: Systemic delivery of P42 peptide: a new weapon to fight Huntington’s disease
NP42T delivery reduces astrogliosis in R6/2 mice. R6/2 mice treated with placebo present an important GFAP positive astrogliosis in the cortex (A) and in the striatum (not shown). R6/2 mice treated with NP42T present lower GFAP positive astrogliosis in the cortex (B) and in the striatum (not shown). Pictures were obtained by laser confocal microscopy (Zeiss LSM 780). The quantification shows that NP42T reduces astrogliosis in the cortex (C) and the striatum (D), but the recovery is not significant. Data represent means +/−SEM (n = 4-7 per group), and were analysed using one way ANOVA: GFAP in the cortex (F(3,19) = 4.9, p < 0.01) and GFAP in the striatum (F(3,18) = 6.1, p < 0.05). Post-hoc comparison (Fisher’s LSD): **p < 0.01 WT (NP) vs R6/2 (NP); ns R6/2 (NP) vs R6/2 (NP42T) in the cortex and *p < 0.05 WT (NP) vs R6/2 (NP); ns R6/2 (NP) vs R6/2 (NP42T) in the striatum.